Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03191617
Other study ID # NEOCOSUR
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 2015
Est. completion date December 2019

Study information

Verified date March 2019
Source NEOCOSUR
Contact Daniela Masoli, MD
Phone 56-9-95453952
Email daniela.masoli@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the study is to compare two human milk fortifiers with different protein content and LCPUFA in a group of very low birth weight infants.


Description:

This study is a multi-center, third party-blinded, randomized, controlled, parallel- group, prospective trial comparing growth with a liquid human milk fortifier with higher protein content and LCPUFA and a control powdered human milk fortifier added to breast milk and fed to premature infants. The trial will be conducted in 11 centers in Chile. The enrollment period is expected to be approximately 18 months. To allow for dropouts, approximately 160 participants will be randomized.


Recruitment information / eligibility

Status Recruiting
Enrollment 160
Est. completion date December 2019
Est. primary completion date August 2019
Accepts healthy volunteers No
Gender All
Age group N/A to 40 Days
Eligibility Inclusion Criteria:

- Premature infant equal or under 31 weeks gestational age at birth

- Birth weight equal or under 1,250 g

- Predominantly fed breast milk (mother's milk or donor milk) on study day 0

- Appropriate birth weight for gestational age (AGA) - defined as birth weight between and inclusive of the 10th and 90th percentiles on the Fenton growth chart

- Singleton or twin birth (both twins do not need to qualify and be randomized into study)

- Birth weight is =1,000 g and participant is = 40 days of age on study day 0

- Birth weight is above 1,000 g and participant is = 30 days of age on study day 0

- Enteral intake of 80 mL/kg/d of unfortified breast milk on study day 0

- Anticipate mother`s willingness to breast milk for at least 28 days from study day 0

- Signed informed consent obtained

Exclusion Criteria:

- History of underlying metabolic or chronic disease, congenital malformation, or any other condition which, in the opinion of the Investigator, is likely to interfere with: the ability of the participant to ingest food, normal growth and development of the participant, or the evaluation of the participant

- 5 minute APGAR score = 4

- Major surgery that required general anesthesia prior to first day study (note: persistent ductus arterious ligation is allowed)

- Received pharmacologic doses of glucocorticoids during 3 consecutive days (72 hours) prior to or on day one of study (physiologic hydrocortisone administration up to 1.5 mg/kg/d is permitted)

- Ventilator-dependent and requiring = 40% fraction of inspired oxygen (FiO2) on day one of study (ventilator dependent and requiring = 40% FiO2 and/or nasal canula, and/or nasal continous positive airway pressure (CPAP) and/or oxygen hood is allowed)

- Grade III or IV bilateral intraventricular hemorrhage (IVH) prior to or on study day one

- Feeding intolerance to breast milk feedings on study day one

- Consumption of more than 3 feedings or 12 hours of continuous feeds of fortified breast milk prior to study day one

- Fluid restriction < 120 mL/kg/d

- History of creatinine >2.0 mg/dL 7 days prior to or on study day one

- Currently receiving or plan use of probiotics

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Human milk fortifier
Fortification of breastmilk with liquid human milk fortifier in premature infants

Locations

Country Name City State
Chile Pontificia universidad Catolica de Chile Santiago Metropolitana

Sponsors (1)

Lead Sponsor Collaborator
NEOCOSUR

Country where clinical trial is conducted

Chile, 

Outcome

Type Measure Description Time frame Safety issue
Primary Weight and linear growth Weight increase in g/K/day and knee-to-heel length increase in mm/weeks, measured in one scale (+-5 g) and one kneenometer (special device to measure longitude) (+- 1mm) by one person for each center between entering study and 45 days in study or discharge between entering study and 45 days in study or discharge, whatever first
Secondary Compare length of hospital- stay days from the first day of study to discharge home ( weight is one criteria for discharge) days from the first day of study to discharge home , an average of 37 weeks of postconceptual age
Secondary Compare feeding tolerance Daily record of residue, regurgitation and suspend of gastric feedings Between entering study and 45 days in study or discharge, if discharge first
Secondary Compare incidence of main preterm morbidities: necrotizing enterocolitis, bronchopulmonary dysplasia, retinopathy of prematurity and sepsis Incidence of necrotizing enterocolitis grade II or more, bronchopulmonary dysplasia as additional oxygen at 36 postconceptual weeks, retinopathy of prematurity with treatment and sepsis with positive hemoculture Between entering study and 45 days in study or discharge, if discharge is first
Secondary Compare cost/benefits . The cost of use a fortificant and the benefit of growth velocity compare cost of total amount of fortifier used compare with cost of number of days of hospitalization, number of days in neonatal intensive care unit in each group. Between entering study and 45 days in study or discharge, if discharge is first
See also
  Status Clinical Trial Phase
Completed NCT01489098 - Effect of the Level of Dietary Protein on Body Composition N/A
Completed NCT02170428 - Diet and Well-being of Young Danish Children
Completed NCT02403739 - Visual Interpretation of Neonatal Growth Charts N/A
Completed NCT02484495 - Extended Pilot Project Community Based Production of Complementary Food in Ethiopia N/A
Withdrawn NCT03673566 - Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - CHMCO N/A
Completed NCT04506541 - The Effects Of KC On Exclusively Breastfeeding And Baby's Growth And Development According To Attachment Theory N/A
Withdrawn NCT03673579 - Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - MHSB N/A
Completed NCT03384719 - The Effect of Milk Protein vs Blends of Milk and Plant Protein on Growth Markers in 7-8 Year Old Healthy Danish Children N/A
Completed NCT02586571 - Growth and Body Composition in Breastfed Infants - Study on Age of Introduction of Complementary Foods in Iceland
Recruiting NCT05604846 - Probiotic Supplementation in Extremely Preterm Infants in Scandinavia N/A
Completed NCT03574350 - Effect on Early Somatic Growth of a Daily Kinesthetic Stimulation on Preterm Infants N/A
Completed NCT02239588 - Evaluation of the Effect of Pure Canterbury Stage 1 Infant Formula Milk Powder on the Growth of Infant 0-6 Months of Age Phase 4